TY - JOUR
T1 - Release of targeted protein nanoparticles from functional bacterial amyloids: A death star-like approach
AU - Unzueta, Ugutz
AU - Cespedes, María Virtudes
AU - Sala, Rita
AU - Alamo, Patricia
AU - Sánchez-Chardi, Alejandro
AU - Pesarrodona, Mireia
AU - Sánchez-García, Laura
AU - Cano-Garrido, Olivia
AU - Villaverde, Antonio
AU - Vázquez, Esther
AU - Mangues, Ramón
AU - Seras-Franzoso, Joaquin
PY - 2018/6/10
Y1 - 2018/6/10
N2 - © 2018 Elsevier B.V. Sustained release of drug delivery systems (DDS) has the capacity to increase cancer treatment efficiency in terms of drug dosage reduction and subsequent decrease of deleterious side effects. In this regard, many biomaterials are being investigated but none offers morphometric and functional plasticity and versatility comparable to protein-based nanoparticles (pNPs). Here we describe a new DDS by which pNPs are fabricated as bacterial inclusion bodies (IB), that can be easily isolated, subcutaneously injected and used as reservoirs for the sustained release of targeted pNPs. Our approach combines the high performance of pNP, regarding specific cell targeting and biodistribution with the IB supramolecular organization, stability and cost effectiveness. This renders a platform able to provide a sustained source of CXCR4-targeted pNPs that selectively accumulate in tumor cells in a CXCR4 + colorectal cancer xenograft model. In addition, the proposed system could be potentially adapted to any other protein construct offering a plethora of possible new therapeutic applications in nanomedicine.
AB - © 2018 Elsevier B.V. Sustained release of drug delivery systems (DDS) has the capacity to increase cancer treatment efficiency in terms of drug dosage reduction and subsequent decrease of deleterious side effects. In this regard, many biomaterials are being investigated but none offers morphometric and functional plasticity and versatility comparable to protein-based nanoparticles (pNPs). Here we describe a new DDS by which pNPs are fabricated as bacterial inclusion bodies (IB), that can be easily isolated, subcutaneously injected and used as reservoirs for the sustained release of targeted pNPs. Our approach combines the high performance of pNP, regarding specific cell targeting and biodistribution with the IB supramolecular organization, stability and cost effectiveness. This renders a platform able to provide a sustained source of CXCR4-targeted pNPs that selectively accumulate in tumor cells in a CXCR4 + colorectal cancer xenograft model. In addition, the proposed system could be potentially adapted to any other protein construct offering a plethora of possible new therapeutic applications in nanomedicine.
U2 - https://doi.org/10.1016/j.jconrel.2018.04.004
DO - https://doi.org/10.1016/j.jconrel.2018.04.004
M3 - Article
SN - 0168-3659
VL - 279
SP - 29
EP - 39
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -
